Halozyme Therapeutics
Nasdaq HALO · San Diego, CA
Works in Dermatology · Immunology · Metabolic & endocrine · Oncology · Renal & urogenital · Women's health
Halozyme Therapeutics is a clinical trial sponsor based in San Diego, CA, listed as Nasdaq HALO. It has 1 active clinical trial with 100 planned participants, across 6 therapeutic areas. Since 2021 it has completed 2 trials and stopped 0 early.
Trial track record · since 2021
Financials · Nasdaq HALO
Pipeline · 1 active trial
| Stage | Trial | Status |
|---|---|---|
On the market
1 approved drug application with a product on the market.
Questions about Halozyme Therapeutics
Halozyme Therapeutics is lead sponsor of 1 active clinical trial on ClinicalTrials.gov, with 100 planned participants, in Dermatology, Immunology, Metabolic & endocrine, Oncology and other areas. Since 2021 it has completed 2 trials and stopped 0 early.
Halozyme Therapeutics is based in San Diego, CA and is listed as Nasdaq HALO. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Halozyme Therapeutics; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-02-18.
Approve Suite is not affiliated with Halozyme Therapeutics.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.